Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex

1996 ◽  
Vol 6 (S1) ◽  
pp. 277-277
Author(s):  
P. J. M. van Kesteren ◽  
P. Lips ◽  
H. Asscheman ◽  
J. A. J. Megens ◽  
L. J. G. Gooren
1998 ◽  
Vol 48 (3) ◽  
pp. 347-354 ◽  
Author(s):  
Paul Van Kesteren ◽  
Paul Lips ◽  
Louis J. G. Gooren ◽  
Henk Asscheman ◽  
Jos Megens

1999 ◽  
Vol 31 (6) ◽  
pp. 2322-2323 ◽  
Author(s):  
A Moreno ◽  
J.V Torregrosa ◽  
F Pons ◽  
J.M Campistol ◽  
M.J Martı́nez de Osaba ◽  
...  

Author(s):  
Himika Chawla ◽  
Soma Saha ◽  
Devasenathipathy Kandaswamy ◽  
Raju Sharma ◽  
Vishnubhatla Sreenivas ◽  
...  

2003 ◽  
Vol 58 (5) ◽  
pp. 617-620 ◽  
Author(s):  
Esteban Jódar ◽  
María Pilar Ruiz Valdepeñas ◽  
Guillermo Martinez ◽  
Antonino Jara ◽  
Federico Hawkins

1994 ◽  
Vol 53 (2) ◽  
pp. 149-149 ◽  
Author(s):  
A M Cooper ◽  
M M O'Sullivan ◽  
D Clements ◽  
J E Compston ◽  
W D Evans ◽  
...  

2016 ◽  
Vol 175 (2) ◽  
pp. 101-106 ◽  
Author(s):  
Filippo Ceccato ◽  
Mattia Barbot ◽  
Nora Albiger ◽  
Marialuisa Zilio ◽  
Pietro De Toni ◽  
...  

Introduction Patients with 21-hydroxylase deficiency (21OHD) assume a lifelong glucocorticoid (GC) therapy. Excessive GC treatment increases the risk of osteoporosis and bone fractures, even though the role of substitutive therapy is not fully established: we analyzed the effect of GC dose on bone metabolism and bone mineral density (BMD) over time in patients with 21OHD. Methods We studied bone metabolism markers and BMD in 38 adult patients with 21OHD (19–47 years, 24 females and 14 males) and 38 matched healthy control. In 15 patients, BMD data were available at both baseline and after a long-term follow-up. Results BMD was lower in patients than in controls at lumbar spine (0.961±0.1g/cm2 vs 1.02±0.113g/cm2, P=0.014) and femur neck (0.736±0.128g/cm2 vs 0.828±0.103g/cm2, P=0.02); otherwise, after height correction, only femoral neck BMD was lower in patients (0.458±0.081g/cm2 vs 0.498±0.063g/cm2, P=0.028). In those 21OHD subjects with at least 10 years follow-up, we observed an increase in lumbar BMD (P=0.0429) and a decrease in femur neck BMD values (P=0.004). Cumulative GC dose was not related to bone metabolism or BMD. No patient experienced clinical fragility fractures. Conclusions BMD values are decreased in patients with 21OHD, which are in part explained by decreased height, but not by the dose of glucocorticoids. Nevertheless, bone status should be carefully monitored in patients with 21OHD.


2007 ◽  
Vol 74 (3) ◽  
pp. 263-269 ◽  
Author(s):  
Hermann Josef Girschick ◽  
Imme Haubitz ◽  
Olaf Hiort ◽  
Peter Schneider

PEDIATRICS ◽  
2008 ◽  
Vol 121 (3) ◽  
pp. e705-e713 ◽  
Author(s):  
K. Wasilewski-Masker ◽  
S. C. Kaste ◽  
M. M. Hudson ◽  
N. Esiashvili ◽  
L. A. Mattano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document